Most public hospitals registered drug ruptures last year, in almost half of cases with severe clinical impact, forcing them to change medication or postpone treatment, concludes a study that will be published today.
© Lusa
20/11/2026
by
Lusa
A most public hospitals registered drug ruptures last year, in almost half of cases with severe clinical impact, forcing them to change medication or postpone treatment, concludes a study that will be published today.
According to the National Medicine Access Index, to which Lusa had access, 97% of the 36 hospitals of the National Health Service (SNS) that responded (of a total of 43) had ruptures, in 47% of the cases with clinical impact considered severe.
“ A rupture that requires changing the therapy of a patient or delaying treatment is no longer just a logistical problem and becomes a quality care problem”, laments Xavier Barreto, president of the Portuguese Association of Hospital Administrators (PAH), responsible for the study.
In statements to Lusa, Xavier Barreto recalls that hospitals “invariably report ruptures” and that “in a significant part” have a clinical impact on patients.
“We are very rarely faced with a case in which the patient is not treated,” he adds, “the patient is treated, but sometimes we postpone treatment or exchange for another molecule that may have a similar effect (...), but it is not the same, and this always has some consequence for the patient”.
According to the data collected, ruptures with clinical impact considered severe forced the change of therapy in 53% of cases and postpone treatments in 35%.
Almost 67% of hospitals say that rupture affects all types of medications and about 31% that essentially affect generics.
Xavier Barreto also warns that hospitals indicate that these ruptures are essentially due to “failures in the centralized purchasing processes of SPMS” [Shared Services of the Ministry of Health], responsible for purchases for all hospitals of the National Health Service (SNS).
“ Sometimes these contests are not launched in a timely manner, and then the medicines arrive late at the hospitals,” said the person responsible, saying that, in addition to these delays, there is a shortage of hospital resources.
Asked about which medicines were broken, more than half (52.9%) replied that it was in drugs to treat cancer, about 30% indicated paracetamol (for pain and fever), 11.8% a specific muscle relaxant and the same percentage reported quetiapine (antipsychotic).
As solutions, hospitals highlight the issuance of opinions with therapeutic alternatives at national level by the National Commission of Pharmacy and Therapy or by Infarmed, the existence of minimum stocks and strategic reserves of critical medicines and the obligation for marketing authorisation holders to have rupture management plans.
Drug expenditure increased last year by 81% of the institutions, with an average increase of 12% over 2024. Oncology appears as the therapeutic area most associated with this increase.
According to Infarmed data, last year SNS hospitals spent EUR 2,523 million on medicines, a value that has risen to two digits since 2020. The expenditure in 2025 on cancer medicines alone was €864.4 million.
All institutions have implemented expenditure control measures, with emphasis on the work of Pharmacy and Therapeutic Commissions (92%) and automatic replacement by biosimilars (89%) and by International Common Name (78%).
The study also indicates that two thirds (67%) of the institutions started clinical trials in 2025, which are considered a factor facilitating access to the medication by 96% of hospitals.
The weight of the administrative burden is the main barrier in the process of buying medicines, identified by 72% of the institutions.
The National Index of Access to Hospital Medicinal Products is a study with technical validation of the Order of Pharmaceuticals and the APAH, which aims to monitor the evolution of access to the drug in the SNS and identify opportunities for improvement.
The results are presented today at the Belém Cultural Center in Lisbon, on the 18th edition of the Medication Forum.




